Low-Concentration Atropine Market Analysis Asia, North America, Europe, Rest of World (ROW) - US, Canada, Germany, China, Japan - Size and Forecast 2024-2028

Published: Dec 2023

Pages: 155

SKU: IRTNTR77089

Snapshot

Low-Concentration Atropine Market 2024-2028

The Global Low-Concentration Atropine Market size is estimated to grow by USD 1,039.97 million at a CAGR of 18.81% between 2023 and 2028.

There has been an increasing awareness regarding the importance of vision. In addition, people around the world are becoming more aware of the need to take care of their eyes and seek appropriate treatment for common vision problems like myopia. Furthermore, this increased awareness is driven by various factors, including advancements in technology, rising healthcare expenditure, and the understanding of the impact that vision problems can have on daily life. Hence, such factors are positively impacting the market.

Technavio has segmented the market into Type, Application, and Geography

The type segment is classified into atropine sulfate 0.01 percentage, atropine sulfate 0.025 percentage, and atropine sulfate 0.05 percentage
The application segment is classified into child and adult
The geography segment includes key regions such as Asia, North America, Europe, and Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Low-Concentration Atropine Market During the Forecast Period?

To learn more about this report, Download Report Sample

Low-Concentration Atropine Market Segmentation by Type, Application, and Geography Analysis

Type Analysis

Atropine sulfate 0.01 percentage

The atropine sulfate 0.01 percentage segment is estimated to witness significant growth during the forecast period. The atropine sulfate 0.01% segment is expected to grow fuelled by the ongoing clinical research to reduce progressive myopia among children and adults. In addition, atropine sulfate 0.01% ophthalmic solution is for topical ophthalmic use and is used to dilate the eye before examination, surgery, or to treat myopia. Furthermore, atropine sulfate 0.01% has been shown to have minimal side effects in children who were 4 to 12 years of age at the start of treatment.

Get a glance at the market contribution of various segments Download PDF Sample

The atropine sulfate 0.01 percentage segment was the largest segment and was valued at USD 268.24 million in 2018. Moreover, due to the growing concern about pathological myopia, research studies focused on slowing the progression of myopia among children have witnessed interest among ophthalmologists. In addition, atropine sulfate 0.01% has emerged as an effective approach. Such developments are fuelling the growth of this segment. Furthermore, companies in the market in focus are coming up with new product launches. For instance, Aspen Australia, a subsidiary of Aspen Pharmacare Holdings Limited, in August 2022, launched new ophthalmic prescription eye drops. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Application Analysis

Child

Various ongoing clinical research and the high prevalence of myopia are fuelling the growth of the segment. In addition, the children segment is expected to grow fuelled by the rising awareness regarding vision care among children. Moreover, with the advent of smartphones, tablets, and other digital devices, children are spending more time in front of screens. In addition, this prolonged screen time has been associated with an increased risk of myopia, particularly in children. Therefore, there is a growing recognition of the importance of early intervention and treatment to prevent the development and progression of myopia. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Adult

There is an increasing prevalence of myopia among adults, also there is a growing demand for vision correction among the aging population. In addition, aging is a major risk factor for visual impairment. Moreover, the proportion of the global geriatric population is expected to nearly double by 2050. In addition, as people age, their eyes undergo various changes that can result in vision problems like myopia. Furthermore, as the global population continues to age, the prevalence of these vision disorders among adults is expected to increase, leading to a larger demand for treatment options. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

Asia is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Factors such as the rising cost of therapeutics and poor healthcare infrastructure in various countries, such as China and India, in the region. In addition, the regional market is primarily driven by the increasing awareness of eye disorders, including myopia. Moreover, in countries such as India, most of the population is unaware of several eye diseases, including myopia. For example, in countries such as India, most of the population is unaware of several eye diseases, including myopia. Thus, to overcome this challenge, World Sight Day is celebrated every year on the second Thursday of October to draw attention toward blindness and vision impairment. Hence, such factors are driving the market growth in Asia during the forecast period.

Buy Full Report Now

Key Low-Concentration Atropine Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 18 market companies, including:

AdvaCare Pharma: The company offers low concentration atropine such as AtroCare.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Low-Concentration Atropine Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Low-Concentration Atropine Market Drivers

One of the key factors driving the low-concentration atropine market growth is the growing demand for vision correction among the aging population. The global low-concentration atropine market is expected to witness an increase in demand fuelled by the growing aging population and their need for vision correction. In addition, this surge in demand for low-concentration atropine can be attributed to various factors such as lifestyle changes, advancements in technology, and increased awareness about vision disorders.

Moreover, one of the primary reasons for the rising demand for low-concentration atropine is the aging population worldwide. Aging is a major risk factor for visual impairment. In addition, lifestyle changes have also contributed to the growing demand for vision correction. Furthermore, with the advent of technology and the increasing use of electronic devices such as smartphones, tablets, and computers, individuals are spending more time engaging in activities that strain their eyes. Hence, such factors are driving the market growth during the forecast period.

Significant Low-Concentration Atropine Market Trends

A key factor shaping the low-concentration atropine market growth is the growing focus on funding for myopia research studies. Many private and public organizations across the world are providing funds or grants for conducting research studies on progressive myopia. For instance, in August 2021, Sydnexis secured USD45 million in Series B financing. In addition, the financing will be used to fund the company lead candidate, SYD-101, through the completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.

Moreover, in December 2022, SUNY College of Optometry received a grant of USD 2.34 million from the National Eye Institute (NEI) for research in examining the cellular and molecular mechanisms controlling eye growth and the development of myopia (nearsightedness). Furthermore, the researchers are focused on providing deep insight into the causes and development of myopia among children. Thus, increasing investments in research studies are positively impacting the market. Therefore, it is expected to drive the market growth during the forecast period.

Major Low-Concentration Atropine Market Challenges

Side effects and uncertainty in the efficacy of low-concentration atropine are some of the key challenges hindering the low-concentration atropine market growth. Low-concentration atropine is a relatively new therapy for myopia progression, but its efficacy and optimal concentration remain uncertain. In addition, atropine with 0.01% concentration witnessed low efficacy. Furthermore, the primary ocular side effects of low-concentration atropine include mydriasis, which leads to photophobia, blurred near vision, and local allergic responses.

Moreover, long usage of low-concentration atropine also causes dilated pupils and dry or irritated eyes, headaches, altered mental status, dry mouth, urinary retention, constipation, and flushing skin. Therefore, the associated side effects can negatively impact the adoption of low-concentration atropine and encourage patients to opt for alternatives with less severe side effects. Thus, the side effects of low-concentration atropine are negatively impacting the market. Hence, such factors are expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Low-Concentration Atropine Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Low-Concentration Atropine Market Customer Landscape

Segment Overview

The low-concentration atropine market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.

Type Outlook
- Atropine sulfate 0.01 percentage
- Atropine sulfate 0.025 percentage
- Atropine sulfate 0.05 percentage
Application Outlook
- Child
- Adult
Geography Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of the World (ROW)
  - Australia
  - Argentina
  - Brazil

Low-Concentration Atropine Market Scope
Report Coverage	Details
Page number	155
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 18.81%
Market Growth 2024-2028	USD 1,039.97 million
Market structure	Fragmented
YoY growth 2023-2024(%)	11.27
Regional analysis	Asia, North America, Europe, and the Rest of the World (ROW)
Performing market contribution	Asia at 36%
Key countries	US, Canada, Germany, China, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AdvaCare Pharma, Aurolab, Bausch Lomb Corp., ENTOD INTERNATIONAL, Eyenovia Inc., Gmt Pharma, Grevis Pharmaceuticals Pvt. Ltd., ISKON REMEDIES and GMT, Jawa Pharmaceuticals India Pvt. Ltd., Medizia Biotech, OSRX Inc., Raymed Pharmaceutical Ltd., Santen Pharmaceutical Co. Ltd., Sydnexis Inc., Tache Pharmacy, Taiwan Biotech Co.,Ltd, Vyluma, and Aspire Pharma Ltd
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Low-Concentration Atropine Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the low-concentration atropine market between 2023 and 2028
Precise estimation of the low-concentration atropine market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across Asia, North America, Europe, and the Rest of the World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of low-concentration atropine market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global low-concentration atropine market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global low-concentration atropine market 2018 - 2022 ($ million)

4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ million)

4.3 Application Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Application Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Atropine sulfate 0.01 percentage - Market size and forecast 2023-2028
- Exhibit 34: Chart on Atropine sulfate 0.01 percentage - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Atropine sulfate 0.01 percentage - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Atropine sulfate 0.01 percentage - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Atropine sulfate 0.01 percentage - Year-over-year growth 2023-2028 (%)

6.4 Atropine sulfate 0.025 percentage - Market size and forecast 2023-2028
- Exhibit 38: Chart on Atropine sulfate 0.025 percentage - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Atropine sulfate 0.025 percentage - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Atropine sulfate 0.025 percentage - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Atropine sulfate 0.025 percentage - Year-over-year growth 2023-2028 (%)

6.5 Atropine sulfate 0.05 percentage - Market size and forecast 2023-2028
- Exhibit 42: Chart on Atropine sulfate 0.05 percentage - Market size and forecast 2023-2028 ($ million)
- Exhibit 43: Data Table on Atropine sulfate 0.05 percentage - Market size and forecast 2023-2028 ($ million)
- Exhibit 44: Chart on Atropine sulfate 0.05 percentage - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Atropine sulfate 0.05 percentage - Year-over-year growth 2023-2028 (%)

6.6 Market opportunity by Type
- Exhibit 46: Market opportunity by Type ($ million)
- Exhibit 47: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Application

7.1 Market segments
- Exhibit 48: Chart on Application - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Application - Market share 2023-2028 (%)

7.2 Comparison by Application
- Exhibit 50: Chart on Comparison by Application
- Exhibit 51: Data Table on Comparison by Application

7.3 Child - Market size and forecast 2023-2028
- Exhibit 52: Chart on Child - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Child - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Child - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Child - Year-over-year growth 2023-2028 (%)

7.4 Adult - Market size and forecast 2023-2028
- Exhibit 56: Chart on Adult - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Adult - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Adult - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Adult - Year-over-year growth 2023-2028 (%)

7.5 Market opportunity by Application
- Exhibit 60: Market opportunity by Application ($ million)
- Exhibit 61: Data Table on Market opportunity by Application ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 Asia - Market size and forecast 2023-2028
- Exhibit 67: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.4 North America - Market size and forecast 2023-2028
- Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.5 Europe - Market size and forecast 2023-2028
- Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 China - Market size and forecast 2023-2028
- Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 Canada - Market size and forecast 2023-2028
- Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.11 Japan - Market size and forecast 2023-2028
- Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 AdvaCare Pharma
- Exhibit 111: AdvaCare Pharma - Overview
- Exhibit 112: AdvaCare Pharma - Product / Service
- Exhibit 113: AdvaCare Pharma - Key offerings

12.4 Bausch Lomb Corp.
- Exhibit 114: Bausch Lomb Corp. - Overview
- Exhibit 115: Bausch Lomb Corp. - Business segments
- Exhibit 116: Bausch Lomb Corp. - Key news
- Exhibit 117: Bausch Lomb Corp. - Key offerings
- Exhibit 118: Bausch Lomb Corp. - Segment focus

12.5 ENTOD INTERNATIONAL
- Exhibit 119: ENTOD INTERNATIONAL - Overview
- Exhibit 120: ENTOD INTERNATIONAL - Key offerings

12.6 Eyenovia Inc.
- Exhibit 121: Eyenovia Inc. - Overview
- Exhibit 122: Eyenovia Inc. - Key offerings

12.7 Gmt Pharma
- Exhibit 123: Gmt Pharma - Overview
- Exhibit 124: Gmt Pharma - Product / Service
- Exhibit 125: Gmt Pharma - Key offerings

12.8 ISKON REMEDIES and GMT
- Exhibit 126: ISKON REMEDIES and GMT - Overview
- Exhibit 127: ISKON REMEDIES and GMT - Product / Service
- Exhibit 128: ISKON REMEDIES and GMT - Key offerings

12.9 Jawa Pharmaceuticals INDIA Pvt. Ltd.
- Exhibit 129: Jawa Pharmaceuticals INDIA Pvt. Ltd. - Overview
- Exhibit 130: Jawa Pharmaceuticals INDIA Pvt. Ltd. - Product / Service
- Exhibit 131: Jawa Pharmaceuticals INDIA Pvt. Ltd. - Key offerings

12.10 Medizia Biotech
- Exhibit 132: Medizia Biotech - Overview
- Exhibit 133: Medizia Biotech - Product / Service
- Exhibit 134: Medizia Biotech - Key offerings

12.11 OSRX Inc.
- Exhibit 135: OSRX Inc. - Overview
- Exhibit 136: OSRX Inc. - Product / Service
- Exhibit 137: OSRX Inc. - Key offerings

12.12 Raymed Pharmaceutical Ltd.
- Exhibit 138: Raymed Pharmaceutical Ltd. - Overview
- Exhibit 139: Raymed Pharmaceutical Ltd. - Product / Service
- Exhibit 140: Raymed Pharmaceutical Ltd. - Key offerings

12.13 Santen Pharmaceutical Co. Ltd.
- Exhibit 141: Santen Pharmaceutical Co. Ltd. - Overview
- Exhibit 142: Santen Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 143: Santen Pharmaceutical Co. Ltd. - Key offerings

12.14 Sydnexis Inc.
- Exhibit 144: Sydnexis Inc. - Overview
- Exhibit 145: Sydnexis Inc. - Product / Service
- Exhibit 146: Sydnexis Inc. - Key offerings

12.15 Tache Pharmacy
- Exhibit 147: Tache Pharmacy - Overview
- Exhibit 148: Tache Pharmacy - Product / Service
- Exhibit 149: Tache Pharmacy - Key offerings

12.16 Taiwan Biotech Co.,Ltd
- Exhibit 150: Taiwan Biotech Co.,Ltd - Overview
- Exhibit 151: Taiwan Biotech Co.,Ltd - Product / Service
- Exhibit 152: Taiwan Biotech Co.,Ltd - Key offerings

12.17 Vyluma
- Exhibit 153: Vyluma - Overview
- Exhibit 154: Vyluma - Product / Service
- Exhibit 155: Vyluma - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 156: Inclusions checklist
- Exhibit 157: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 158: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 159: Research methodology
- Exhibit 160: Validation techniques employed for market sizing
- Exhibit 161: Information sources

13.5 List of abbreviations
- Exhibit 162: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

low-concentration atropine market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis